What it's for (Indications)
- Alprostadil + cyclodextrin is primarily indicated for the treatment of chronic arterial occlusive disease (Fontaine stages III and IV) in adults, particularly when revascularization procedures (surgical or endovascular) are not feasible or have been unsuccessful.
- This includes patients experiencing severe peripheral artery disease with critical limb ischemia, characterized by rest pain, ischemic ulcers, or gangrene.
- The aim of therapy is to improve blood flow to the ischemic limbs, alleviate pain, promote healing of trophic lesions, and prevent major amputation.
- It is utilized in situations where the severity of the disease poses a significant threat to limb viability, and other therapeutic options are limited or contraindicated.
- The formulation containing cyclodextrin facilitates the solubilization and stability of alprostadil, enabling its effective intravenous administration.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of alprostadil + cyclodextrin is typically administered as a slow intravenous infusion. For adults, the standard regimen often involves 20 to 60 micrograms (mcg) of alprostadil per day. This can be given as a single daily infusion over 2-3 hours or, for higher doses, divided into two infusions per day. For example, 20 mcg infused over 2 hours, twice daily, or 60 mcg infused over 3-6 hours, once daily. The specific dose and infusion rate must be carefully titrated based on the patient's clinical response and tolerability, with close monitoring of hemodynamic parameters. The medicine must be diluted in physiological saline (0.9% sodium chloride) or 5% glucose solution before infusion. The duration of treatment usually ranges from 2 to 4 weeks, although longer courses may be considered based on individual patient response and physician discretion. Dose adjustments may be necessary in patients with renal or hepatic impairment, requiring reduced doses and careful monitoring. |
Safety & Warnings
Common Side Effects
- Common side effects associated with alprostadil + cyclodextrin infusion are generally related to its vasodilatory properties.
- These include headache, dizziness, flushing, nausea, vomiting, diarrhea, and a feeling of warmth or sweating.
- Localized reactions at the infusion site such as pain, erythema, swelling, or phlebitis are also frequently observed.
- Less common but more serious adverse events can include dose-dependent hypotension, tachycardia, cardiac arrhythmias, chest pain (angina-like symptoms), dyspnea, and elevations in liver enzyme levels.
- Rarely, more severe reactions such as acute heart failure, pulmonary edema (particularly in patients with pre-existing cardiac conditions), severe allergic reactions, or cerebral hemorrhage have been reported, especially with rapid infusion or in susceptible individuals.
- Vigilant monitoring during and after infusion is crucial to identify and manage these potential side effects promptly.
Serious Warnings
- Black Box Warning: Intravenous alprostadil (in combination with cyclodextrin) is indicated for severe forms of peripheral arterial occlusive disease (PAOD), particularly critical limb ischemia, where revascularization procedures are not feasible or have failed. Due to its potent vasodilatory effects and impact on cardiovascular hemodynamics, serious warnings are warranted. This medication can cause significant systemic hypotension, tachycardia, and fluid retention, which may lead to or exacerbate congestive heart failure, especially in patients with pre-existing cardiac conditions. Careful monitoring of cardiac function, blood pressure, and fluid balance is imperative during and after infusion. Patients with unstable angina, recent myocardial infarction, or severe heart failure are at particularly high risk. The treatment should be initiated and managed only by physicians experienced in treating PAOD and capable of continuous patient monitoring in an appropriate clinical setting. There is also a risk of local irritation or inflammation at the infusion site, and the potential for exacerbation of bleeding in patients with underlying coagulopathies or those receiving concomitant anticoagulant therapy. Patients must be carefully selected and monitored throughout the entire course of treatment to mitigate these serious risks.
- Alprostadil + cyclodextrin is contraindicated in patients with severe cardiac insufficiency (NYHA Class III/IV), recent myocardial infarction (within 6 months), severe unstable angina pectoris, or severe arrhythmias.
- It should not be used in individuals with acute pulmonary edema, severe chronic obstructive pulmonary disease (COPD), or in those with a history of cerebral hemorrhage or stroke within the past 6 months.
- Patients with severe hepatic or renal impairment (e.
- g.
- , creatinine clearance < 30 mL/min) require significant dose reduction and extremely cautious administration due to the risk of fluid overload and altered drug metabolism.
- Close monitoring of cardiac function, blood pressure, heart rate, and fluid balance is imperative throughout the treatment course, particularly in elderly patients or those with pre-existing cardiovascular compromise.
- Concomitant use with anticoagulants or antiplatelet agents increases the risk of bleeding.
- The drug is contraindicated in pregnancy and lactation.
- Any signs of fluid retention, severe hypotension, or cardiac decompensation necessitate immediate cessation or reduction of the infusion rate.
How it Works (Mechanism of Action)
Alprostadil is a synthetic analogue of prostaglandin E1 (PGE1), a naturally occurring eicosanoid with potent pharmacological actions. Its primary mechanism of action involves direct relaxation of vascular smooth muscle cells, leading to marked peripheral and systemic vasodilation, thereby increasing blood flow to ischemic tissues in the affected limbs. Beyond vasodilation, alprostadil exerts several beneficial effects on the microcirculation: it inhibits platelet aggregation, reducing the risk of thrombus formation and improving erythrocyte deformability, which enhances blood flow through constricted capillaries. Furthermore, alprostadil possesses anti-inflammatory and cytoprotective properties; it reduces leukocyte adhesion to endothelial cells, modulates the release of inflammatory mediators, and protects vascular endothelium from damage. These combined actions help alleviate critical limb ischemia, promote healing of trophic ulcers, and reduce pain. Cyclodextrin in the formulation is an excipient that forms a stable complex with alprostadil, significantly improving its aqueous solubility and stability, which is essential for its intravenous administration and sustained therapeutic effect.
Commercial Brands (Alternatives)
No other brands found for this formula.